Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis

Next Previous
Trial Profile

A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Velmanase alfa (Primary)
  • Indications Alpha-Mannosidosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms rhLAMAN-07
  • Sponsors Chiesi Farmaceutici; Zymenex A/S

    • Most Recent Events

    • 06 Sep 2023 According to a Chiesi media release, updated integrated analysis of data from phase I/II, III, and follow-up clinical trials presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 being held August 29 - September 1, 2023, in Jerusalem, Israel.
    • 08 Nov 2022 Status changed from recruiting to completed.
    • 20 Jul 2020 Status changed from active, no longer recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top